Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
Open Access

Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy

Chang Liu, Binglu Cheng, Gang Zhao, Hengjie Yuan
DOI: 10.1136/jim-2022-002339 Published 15 August 2022
Chang Liu
1 Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China
2 Department of Wuqing District, Tianjin Institute for Drug Control, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Binglu Cheng
3 Department of Anus and Intestine Surgery, Tianjin Fourth Central Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Zhao
2 Department of Wuqing District, Tianjin Institute for Drug Control, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hengjie Yuan
1 Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hengjie Yuan
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    The basic information of patients (n=118)

    ItemsCases
    Sex
     Female118
     Male0
    Age
     ≤40 years old12
     40 years old and ≤60 years old62
     >60 years old44
    Therapeutic regime
     AT75
     TAC43
    Patients with hypertension, coronary heart disease or diabetes before chemotherapy0
    The total number of patients118
  • Table 2

    Analysis of the echocardiograms of the patients before, during and after chemotherapy

    Clinical characteristicsBefore chemotherapy (Embedded Image ̄±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    LVEF (%)64.458±3.71364.169±3.31463.992±3.6360.598(B)0.8960.7000.971
    LAMAD (mm)31.508±3.48631.915±3.98831.966±4.1180.610(B)0.7890.7341.000
    RAMD (mm)29.619±2.27629.644±2.56729.542±2.3950.945(B)1.0000.9920.985
    LVEDD (mm)42.203±3.01442.115±3.34641.915±3.1070.773(B)0.9950.8510.951
    LVESD (mm)26.822±2.79727.000±2.89727.195±2.5960.585(B)0.9500.6400.929
    RVID (mm)14.627±1.64214.814±2.33515.093±3.3200.3630.5710.1580.396
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

    • LAMAD, left atrial maximum anteroposterior diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; RAMD, right atrial mediolateral diameter; RVID, right ventricular internal dimension.

  • Table 3

    Analysis of the echocardiograms of the patients before, during and after chemotherapy

    Clinical characteristicsBefore chemotherapy (Embedded Image ±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    Heart rate
    (times/min)
    74.017±11.19580.627±13.39181.373±13.312<0.001(B)<0.001<0.0010.963
    P-wave time (s)0.107±0.0100.106±0.0130.105±0.0110.193(B)0.6320.1530.875
    P-R interphase (s)0.152±0.0200.153±0.0190.151±0.0180.696(B)1.0000.8710.801
    QRS complex (s)0.086±0.0100.086±0.0080.086±0.0080.968(B)0.9951.0000.993
    Q-T interphase (s)0.399±0.0360.398±0.0400.397±0.0400.891(B)0.9890.9480.989
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

  • Table 4

    Statistical analysis results of ST-segment abnormalities and T wave abnormalities

    Clinical characteristicsBefore chemotherapy (%)During chemotherapy (%)After chemotherapy (%)P12 P13 P23
    ST-segment abnormalities16.9525.4234.750.1110.0020.118
    T wave abnormalities27.1226.2737.290.8830.0950.069
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

  • Table 5

    Statistical analysis of myocardial enzymes

    Clinical characteristicsBefore chemotherapy (Embedded Image ±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    Creatine kinase (U/L)42.555±15.34043.892±25.46753.331±37.0240.0050.7080.0030.009
    Creatine kinase isoenzyme (U/L)11.678±6.78711.794±6.10711.748±5.8570.990(B)0.9991.0001.000
    Lactate dehydrogenase (U/L)180.118±36.402179.927±35.885192.522±42.1500.016(B)1.0000.0480.042
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

  • Table 6

    Statistical analysis of blood tests

    Clinical characteristicsBefore chemotherapy (Embedded Image ±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    Hemoglobin (g/L)129.280±12.762115.381±12.752116.881±12.900<0.001(B)<0.001<0.0010.749
    Albumin (g/L)42.636±3.93239.973±3.63340.080±4.127<0.001(B)<0.001<0.0010.995
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

  • Table 7

    Statistical analysis of blood tests

    Clinical characteristicsBefore chemotherapy (Embedded Image ±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    Fasting blood glucose (mmol/L)5.632±2.1805.391±1.3855.660±2.0040.484(B)0.6720.9990.544
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

  • Table 8

    Statistical analysis of blood tests

    Clinical characteristicsBefore chemotherapy (Embedded Image ±s)During chemotherapy (Embedded Image ±s)After chemotherapy (Embedded Image ±s)F(B) or χ²P12 P13 P23
    Total cholesterol (mmol/L)5.695±4.0425.557±1.0325.566±1.0500.892(B)0.9780.9821.000
    Triglyceride (mmol/L)1.360±0.6371.903±1.0711.939±0.843<0.001<0.001<0.0010.748
    Low-density lipoprotein (mmol/L)3.388±0.8633.461±0.9283.506±0.9010.594(B)0.8950.6630.975
    High-density lipoprotein (mmol/L)1.519±0.3561.451±0.3241.396±0.3400.021(B)0.3250.0200.494
    • P12, P13 and P23 represent the calculation results of corresponding tests for indicators before and during chemotherapy, before and after chemotherapy, and during and after chemotherapy, respectively.

PreviousNext
Back to top
Vol 70 Issue 6 Table of Contents
Journal of Investigative Medicine: 70 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
Chang Liu, Binglu Cheng, Gang Zhao, Hengjie Yuan
Journal of Investigative Medicine Aug 2022, 70 (6) 1352-1357; DOI: 10.1136/jim-2022-002339

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
Chang Liu, Binglu Cheng, Gang Zhao, Hengjie Yuan
Journal of Investigative Medicine Aug 2022, 70 (6) 1352-1357; DOI: 10.1136/jim-2022-002339
Download PDF

Share
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
Chang Liu, Binglu Cheng, Gang Zhao, Hengjie Yuan
Journal of Investigative Medicine Aug 2022, 70 (6) 1352-1357; DOI: 10.1136/jim-2022-002339
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Data availability statement
    • Ethics statements
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of statins on outcomes in Hispanic patients with COVID-19
  • Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease
  • Acute myocardial infarction and concomitant acute intracranial hemorrhage: clinical characteristics and outcomes
Show more Original research

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research